Used in the treatment of moderate to severe asthma, particularly in patients with elevated biomarkers of type 2 inflammation. It targets and neutralizes interleukin-33 (IL-33), a key upstream cytokine involved in initiating and amplifying allergic inflammatory responses. By blocking IL-33, it helps reduce airway inflammation, improve lung function, and decrease the frequency of asthma exacerbations. Also under investigation for use in chronic obstructive pulmonary disease (COPD) and atopic dermatitis, showing potential in reducing symptoms and improving patient outcomes in early clinical trials. Administered via subcutaneous injection, it offers a targeted biologic therapy option for patients unresponsive to standard treatments.